What we know about the Alzheimer's drug Health Canada approved

Health Canada has conditionally approved the drug lecanemab to slow early-stage Alzheimer's disease, raising questions about ...

Alzheimer’s pill could reduce brain decline in some high-risk patients, trial suggests

The experimental pill ALZ-801 slowed memory decline by 50% and reduced brain shrinkage in early Alzheimer's patients with ...
Healio

Donanemab improves outcomes in early-stage Alzheimer’s disease up to 3 years

Please provide your email address to receive an email when new articles are posted on . Earlier initiation of donanemab reduced the risk of disease progression on the Clinical Dementia Rating-Global ...
South Florida Reporter

First Alzheimer’s Pill For Genetically At High Risk Shows Promise In Phase 3 Trial

Fact checked by Amanda Ward One gene variant that is particularly associated with Alzheimer’s disease risk is APOE4. Resear ...

40Hz sensory stimulation may benefit some Alzheimer's patients for years, small study suggests

A new research paper documents the outcomes of five volunteers who continued to receive 40Hz light and sound stimulation for ...

United States Alzheimer Drugs Research Report 2025: Market to Reach $4.47 Billion by 2033 - 7.78% CAGR Fueled by Drug Innovation and Early Diagnosis

Growth fueled by the increasing incidence of Alzheimer's disease, growing aging population, and continued development in ...

Algernon Announces CAD $4 Million Non-Dilutive Financing to Open Four Brain-Specific PET Scan Clinics in the U.S. for Early Stage Alzheimer’s Detection

Detailed price information for Algernon Health Inc (AGNPF) from The Globe and Mail including charting and trades.